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Abstract
Objective
To investigate the relationship between cerebrospinal fluid (CSF) β-amyloid peptide (Aβ42)
and CSF Tau in a large population of patients referred to memory clinics for investigation of
cognitive dysfunction.
Methods
We analyzed Alzheimer’s disease (AD) biomarkers in CSF taken from 3565 patients
referred to 18 French memory clinics. Patients were classified into four profiles according to
levels of CSF biomarkers (A: amyloidosis, N: neurodegeneration). The association between
CSF Tau and CSF Aβ42 were analyzed using general linear regression models, in the over-
all population and stratified by biomarkers profiles. We compared linear and quadratic mod-
els using Akaike information criterion. We also assessed change in biomarker profiles in a
subset of patients who had 2 assessments of biomarkers.
Results
CSF Tau was negatively associated with CSF Aβ42 in the overall population, following a
non-linear quadratic model. However, the nature of this association was different in the 4
profiles: positive association in A-N- profile, negative association in A-N+ and A+N+ profiles,
lack of association in A+N- patients. When considering patients with longitudinal data on
profiles, 36% of those initially classified as A-N+ evolved to an A+N+ profile.
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Conclusions
The nature of the association between CSF Aβ42 and CFS Tau depends on the A/N profiles
of patients. These results suggest an increase in CSF Aβ42 early in the disease before its
decline while tau pathology progresses, this pattern is particularly observed in non-APOE4
subjects. This phenomenon may explain why some patients with neurodegeneration only
markers convert to an AD profile (A+N+) over time.
Introduction
Alzheimer’s disease (AD), the most common cause of dementia, is neuropathologically charac-
terized by extracellular β-amyloid peptide (Aβ42) deposits, neurofibrillary tangles composed
of intraneuronal abnormally phosphorylated Tau, and neuronal and synaptic loss [1]. Accord-
ing to the “amyloid cascade” hypothesis [2], extracellular accumulation of Aβ is the first step,
successively followed by deposits of neurofibrillary tangles, neuronal death and finally the clin-
ical onset of symptoms [3]. A competing hypothesis is that neurofibrillary tangles appear first,
particularly in sporadic AD [4, 5].
The development of AD biomarkers during the past decade allows new opportunities for
studying the in-vivo kinetics of amyloid and tau lesions [6, 7]. Cerebrospinal fluid (CSF) mea-
surement of Aβ42 has been shown to be inversely correlated with total brain Aβ load [8], while
CSF tau levels positively correlated with the presence of neocortical neurofibrillary tangles [9].
Based on the amyloid hypothesis, a temporal chronology of AD biomarkers has been proposed
[10], and in 2011 the National Institute on Aging-Alzheimer’s Association (NIA-AA) pro-
posed biomarker based recommendations for the staging of preclinical AD [11]. Using evi-
dence of amyloidosis (A) and neurodegeneration (N), Stage 1 corresponds to presence of Aβ
deposits and the absence of neurodegeneration (A+N-), while stage 2/3 corresponds presence
of both markers (A+N+), without or with subtle cognitive decline. One year after the publica-
tion of the NIA-AA recommendations, Jack et al. reported an additional category of subjects,
characterized by positivity for only neurodegeneration markers (A-N+) and proposed the des-
ignation of SNAP, for Suspected Non-Alzheimer’s disease Pathophysiology for these subjects
[12].
The concept of SNAP (A-N+) remains the subject of debate [13]. Several studies have
shown accelerated cognitive decline in these persons [14–17], with poorer clinical prognosis
than A+N- subjects [18]. However, other studies found no differences between SNAP and
A-N- subjects in cognitive decline, while the A+N- and A+N+ groups declined faster [19–21].
It is worth noting that the precise biomarkers used to define SNAP remains heterogeneous
across studies, some use CSF Tau or phosphorylated Tau, or T1-weighted structural MRI, and/
or FDG PET imaging data.
CSF allows assessment of both Aβ42 and Tau, the hallmarks of AD, but their relationship
remains poorly understood. A recent study based on data on 766 subjects from 3 independent
cohorts found a non-linear quadratic association between CSF Tau and Aβ42 [22]. In the pres-
ent study, we aim to extend these analyses using data on 3,565 patients in order to cover a wide
spectrum of AD pathology. We test the hypothesis that the nature of the association between
these biomarkers depends on the AD “profile” of patients. In further analysis on patients who
had 2 lumbar punctures we analyzed the longitudinal change in biomarkers profiles to test the
hypothesis that persons initially classified as SNAP may evolve to an AD profile.
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Methods
Subjects
Following national recommendations, CSF analyses are routinely undertaken in patients with
cognitive signs referred to hospital-based memory centers in France [23, 24]. For the present
study, CSF biomarkers from 18 hospitals in and around Paris, France, were aggregated in one
biochemistry department. All patients seen between January 1st 2008 and January 1st 2018 for
whom AD biomarkers from CSF were available were included in the analysis; methods and char-
acteristics of the population have been previously reported elsewhere [25, 26]. The study was
approved by the Ethical Committee of Paris University Hospitals. Patients under legal protection
were excluded. Written consent was signed in priority by the patients, and in case of inability to
sign, by their caregivers. The consent procedure was approved by the local ethical committee.
CSF analysis
Lumbar puncture was performed on patients in a fasting state, typically between 9 and 12 am.
All centers used the same model of 10 mL polypropylene tube to collect CSF (January 2008 to
November 2012: CML model TC10PCS; December 2012 to January 2018: Sarstedt catalog no.
62.610.201). CSF samples were centrifuged at 1,000 g for 10 minutes at 4˚C within 4 hours of col-
lection, and then aliquoted in 0.5 mL polypropylene tubes and stored at -80˚C for further analy-
sis. CSF levels of Aβ42, total Tau, and pTau-181 were measured with the commercially available
sandwich ELISA INNOTEST, using the manufacturer’s procedures (Fujirebio Europe NV, for-
mely Innogenetics NV). The Alzheimer’s Association quality control program for CSF biomark-
ers validated the quality of CSF evaluations of the hospital biochemistry department [27].
Profiles based on CSF biomarkers
The CSF biomarker profiles were used to determine the “profile” of every subject using the
NIA-AA staging framework [11]. The amyloidosis profile (A+N-) was characterized by a low
level of CSF Aβ42 and normal levels of CSF Tau and CSF p-Tau 181. The amyloidosis com-
bined with neurodegeneration profile (A+N+) was defined by a low level of CSF Aβ42 and
increased level of CSF Tau and/or CSF p-Tau 181. Subjects with high levels of CSF Tau and/or
CSF p-Tau 181 but normal Aβ42 were classified as SNAP (A-N+). Those with normal levels of
all three biomarkers were classified as “normal” (A-N-).
In this study we chose not to use the recently proposed A/T/N classification[18, 28] as we
have previously showed that some profiles (A-T+N-, A+T+N-) were quite rare, representing
less than 1% of the sample [25]. Furthermore, in our data CSF Tau and CSF p-Tau 181 were
highly correlated (Spearman coefficient correlation = 0.84, P<0.001).
Abnormal values of CSF biomarkers were defined using thresholds used routinely in clini-
cal practice based on higher Youden index in order to discriminate AD patients from non-AD
patients (i.e. best compromise for sensitivity and specificity). The type of the polypropylene
tube changed in November 2012, and the ELISA INNOTEST sandwich changed on May 1st
2016, requiring adjustment of thresholds at these 2 dates. The cut-offs for CSF Aβ42, Tau and
p-Tau 181 moved respectively from 500/300/65 pg/mL [29] to 730/300/58 pg/mL [25] after the
change of tube.
Covariates
These included age, sex, and performance on the 30-item Mini Mental State Examination
(MMSE) for an assessment of general cognitive status. APOEe4 status was known for a sub-
sample of 1034 individuals.
CSF biomarkers associations in Alzheimer’s disease
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Statistical analysis
Participant characteristics were presented overall and by profiles defined using NIA-AA CSF
biomarkers (A-N-, A+N-, A+N+, A-N+). Proportions were calculated for categorical variables,
while means and standard deviations were computed for continuous variables. Differences as
a function of profiles were assessed using a χ2 test or Student t-test as appropriate.
The association between CSF Tau and Aβ42 was examined using general linear regression
models with CSF Aβ42 as the dependent variable (PROC GLM of SAS). The analysis was ini-
tially adjusted only for the type of collection tube (unadjusted model), and then further
adjusted for age, sex, and APOEe4 status. Analysis were first undertaken in the total sample
and then stratified by the 4 profiles (A-N-, A+N-, A+N+, A-N+). The difference in the associa-
tion between CSF Tau and Aβ42 in the 4 profiles was tested formally using interaction terms
in the linear regression models.
We compared the linear model (Aβ42 = α + β xTau) to the quadratic model (Aβ42 = α + β
xTau + γ x Tau2) following the Akaike information criterion (AIC), with lower AIC values des-
ignating better model fit [30]. Linear and quadratic models were compared in the overall pop-
ulation and then separately in each profile (A-N-, A+N-, A+N+, A-N+).
In the sub-sample with APOEe4 data (N = 1034) we examined the association between CSF
Aβ42 and CSF Tau by first plotting the mean values of CSF Aβ42 as a function of deciles of
CSF Tau in those with an APOEe4 allele versus none. These associations were also examined
in linear regression analysis, adjusted for collection tube, age and sex, in two groups based on
median CSF Tau.
Finally, in persons with 2 lumbar punctures with CSF AD biomarkers, we examined the
evolution of their biomarkers profiles to assess conversion in stage of AD pathology.
The CSF biomarkers were not normally distributed and we followed the approach used by
other teams by log-transforming CSF Tau and using CSF Aβ42 without any transformation in
the statistical models [22]. CSF Tau and CSF phosphorylated Tau were highly correlated in
our sample leading us to use CSF Tau in the main analyses; use of CSF p-Tau 181 in place of
CSF Tau led to similar findings and conclusions.
All p-values were two-tailed and p�0.05 was considered statistically significant. Statistical
analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Results
CSF biomarker data were available on 3565 persons, assessed between January 1st, 2008 and
January 1st, 2018 in one of the 18 memory clinics included in the study. Their characteristics
are summarized in Table 1. The mean (SD) age was 69.8 (10.3) years, 50% were women, and
the mean (SD) MMSE at the time of the lumbar puncture was 21.7 (6.0). Of the 3565 persons
in the sample, 27% had a normal biomarker profile (A-N-), 36% had an AD profile (A+N+),
22% were positive only for amyloid (A+N-), and 15% had the SNAP profile—positive only for
neurodegeneration (A-N+). Compared to the normal profile, patients with an AD profile were
older, more often women, had a lower MMSE scores and were more likely to carry at least one
APOE ε4 allele.
There was an inverse association between CSF Tau and CSF Aβ42 when the study popula-
tion was considered together (β[SE] = -82.1[6.7], p<0.001, Table 2). In analysis stratified by
profiles, CSF Tau was positively associated with CSF Aβ42 in A-N- subjects (β[SE] = 153.6
[17.7]), and negatively associated with CSF Aβ42 among A+N+ (β[SE] = -19.7[7.2]) and A-N
+ subjects (-125.2[22.9]), while no significant association was observed in A+N- patients.
These associations were robust to adjustment for age, sex, and APOE4 status. The test for
CSF biomarkers associations in Alzheimer’s disease
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interaction was highly significant (<0.001) suggesting that the association between CSF Aβ42
and CSF Tau differed in the four profile groups.
Comparisons of linear and quadratic models for the association between CSF Tau and CSF
Aβ42 are presented in S1 Table. The quadratic model fitted the data better in the total study
population (delta AIC = 43). However, this was not the case in all profile sub-groups as the
quadratic model was inferior to the linear model for A-N-, A+N- and A+N+ profiles (delta
AIC = -2), and was only better than the linear model in A-N+ patients (delta AIC = 8). The
scatter plot of CSF Aβ42 and CSF Tau is presented in Fig 1, in the total study population and
in the profiles defined by biomarkers.
Fig 2 shows the mean CSF Aβ42 value as a function of deciles of CSF Tau in APOE4 positive
and negative participants. In APOE4 negative subjects, the mean value of CSF Aβ42 increased
from the first to the 5th decile of CSF Tau (β[SE] = 49.9[9.9], p<0.001), and then decreased
for subjects with higher CSF Tau levels (β[SE] = -83.3[12.5], p<0.001). For APOE4 positive
subjects, there was no association between CSF Aβ42 and CSF Tau stable until the 5th decile
(β[SE] = -10.6[17.4], p = 0.54), and then decreased for those with higher CSF Tau values (β
[SE] = -16.6[8.5], p = 0.05).
Table 1. Characteristics of the study population, overall and as a function of profiles defined by CSF biomarkers. Profiles are based on CSF Aβ42, CSF Tau, and CSF
p-Tau (NIA-AA classification): A-N-: normal levels of all three biomarkers; A+N-: low level of CSF Aβ42 and normal levels of CSF Tau and CSF p-Tau 181; A+N+: lowe
level of CSF Aβ42 and increased level of CSF Tau and/or CSF p-Tau 181; A-N+: high CSF Tau and/or CSF p-Tau 181 but normal Aβ42.
Profiles defined by CSF biomarkers
Overall A-N- A+N- A+N+ A-N+
Characteristics (N = 3565) (N = 947) (N = 789) (N = 1299) (N = 527) P value
Age, years, mean (SD) 69.8 (10.3) 66.0 (11.1) 69.9 (10.5) 72.2 (9.1) 70.7 (9.7) <0.001
Women, n (%) 1770 (49.7) 437 (46.2) 348 (44.1) 739 (56.9) 246 (46.7) <0.001
MMSE, mean (SD) 21.7 (6.0) 23.7 (5.1) 21.6 (6.2) 20.0 (6.2) 22.5 (5.1) <0.001
Education levels, years, mean (SD) 10.1 (4.5) 10.1 (4.6) 10.2 (4.6) 10.0 (4.4) 9.9 (4.3) 0.78
APOEε4 carriers, n (%)a 430 (41.6) 61 (19.2) 57 (50.4) 267 (60.5) 45 (27.8) <0.001
CSF biomarkers (pg/ml), Mean (SD)
Aβ42 682.1 (291.4) 942.1 (198.8) 517.7 (161.4) 479.6 (138.1) 961.3 (275.2) <0.001
Tau 404.9 (326.3) 199.2 (56.6) 179.7 (67.8) 645.3 (344.6) 519.1 (327.2) <0.001
p-Tau 181 60.4 (36.0) 38.8 (10.6) 33.0 (12.1) 88.5 (38.4) 70.9 (26.6) <0.001
aAPOE genotype determined in a sub sample of 1034 patients.
https://doi.org/10.1371/journal.pone.0217026.t001
Table 2. Association between CSF Tau (log transformed) and CSF Aβ42, linear regression analysis. Profiles are based on CSF Aβ42, CSF Tau, and CSF p-Tau
(NIA-AA classification).
Unadjusteda Adjustedb
Population N β(SE) P β(SE) P
Overall 3565 -82.1 (6.7) <0.001 -65.1 (6.7) <0.001
Profiles
A-N- 947 153.6 (17.7) <0.001 178.5 (17.6) <0.001
A+N- 789 18.7 (11.9) 0.12 22.9 (12.1) 0.06
A+N+ 1299 -19.7 (7.2) 0.006 -20.0 (7.1) 0.005
A-N+ 527 -125.2 (22.9) <0.001 -116.5 (22.5) <0.001
aAdjusted for nature of the tube.
bAdjusted for the tube, age, gender, APOE4 status.
https://doi.org/10.1371/journal.pone.0217026.t002
CSF biomarkers associations in Alzheimer’s disease
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Finally, Table 3 presents the evolution of profiles among the 70 patients who had 2 lumbar
punctures, over a median follow-up of 2.1 years. Of the 23 patients initially classified as A+N-
profile, 61% of them remained A+N- at the 2d assessment, and 13% of them evolved to A+N
+ profile. For the 14 patients initially classified as A-N+ profile, 50% had the same profile and
36% evolved to an A+N+ profile.
Discussion
We report the following findings on the relationship between CSF Tau and CSF Aβ42 in a
large, multicentric cohort of 3565 patients assessed for cognitive disorders:
• We confirmed the previously reported quadratic relationship [22] between these 2 biomark-
ers in the total population not stratified by biomarker profiles.
• Further analysis revealed that the association between CSF Tau and CSF Aβ42 is strongly
dependant on biomarkers profiles. This association was positive in those with a normal pro-
file, no association was found in amyloidosis only subjects, and an inverse association in
those with SNAP and AD profiles. The association between CSF Tau and CSF Aβ42 was lin-
ear and not quadratic when examined separately in each profile group.
Fig 1. Scatter plot of CSF Aβ42 and log transformed CSF Tau. A. In the total study population. The quadratic model
is presented in green. B. In analysis separately in each profile. Green: A-N-, brown: A+N-, orange: A-N+, red: A+N+.
Linear regression models are presented and Spearman correlation coefficients.
https://doi.org/10.1371/journal.pone.0217026.g001
Fig 2. Mean CSF Aβ42 by deciles of CSF Tau, as a function of APOE4 status. Green line: No APOE ε4 allele. Red
line: at least one APOE ε4 allele. The linear regression coefficients show analysis between CSF Aβ42 and deciles of CSF
Tau are presented by APOE4 status, stratified by the median of CSF Tau.
https://doi.org/10.1371/journal.pone.0217026.g002
CSF biomarkers associations in Alzheimer’s disease
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• Analysis of change in biomarkers showed that 36% of those who were initially classified as
A-N+ evolved to an A+N+ profile, compared to 13% for those who were initially classified as
A+N-.
We propose a theoretical framework to explain these results which suggest two distinct pat-
terns, illustrated by Fig 3. The first pattern is characterized by biomarkers in normal range
where level of Aβ42 in the CSF increases with level of CSF Tau reflecting early stage of AD.
This stage corresponds to an increase in production and/or decrease in degradation of Aβ42 in
the brain which is still being compensated by an increase in its clearance into the CSF. At
some point in disease progression systems responsible for clearing Aβ42 from the brain into
the CSF become overwhelmed [31] and Aβ42 accumulates in plaques in the brain and CSF
Aβ42 levels decrease while CSF Tau continues to increase to abnormal levels, reflecting the
progression of tau pathology. Within this pattern, some A-N+ patients evolve to future AD
profile as they are simply in the phase that follows the initial increase of CSF Aβ42. This would
explain why one third of our patients initially classified as A-N+ finally evolve to an A+N+ pro-
file with biomarkers assessed at the second lumbar puncture. In the second pattern shown in
Fig 3, level of CSF Aβ42 remains low and stable during the initial progression of Tau pathology
(A+N- patients) to the point where CSF Aβ42 begins to decrease inversely with CSF Tau (A+N
+). Interestingly, these two patterns of change in biomarkers reflect that we found in analyses
stratified by APOEe4 status; patients without APOE4 allele correspond to the first pattern: ini-
tial increase and then decrease of CSF Aβ42 with progression of CSF tau, while patients with at
least one APOE4 allele correspond to the second pattern: initial stability (A+N-) and then
decrease of CSF Aβ42 with progression of tau pathology.
The kinetics of CSF Aβ42 in very early stages of sporadic AD remains largely unknown.
Data from studies on carriers of autosomal-dominant AD mutations,[32, 33] as well as from
experimental studies [34], suggest that CSF Aβ42 levels increase before and during the early
phase of brain amyloid deposition. In their study on biomarker changes in dominantly inher-
ited Alzheimer’s disease, Bateman et al. reported that CSF Aβ42 levels were higher in persons
with autosomal dominant AD 20 to 30 years before the clinical onset of the disease [32], the
earliest observed phenomenon associated with AD.
In the recently proposed biological diagnosis of AD based on the A/T/N classification, A-T
+ profiles are considered to be non-AD pathologic change [28]. Our findings suggest that this
conclusion may need to be tempered in light of our findings that some of these subjects also
evolve towards an AD profile. The neuropathological concept of “primary age-related tauopa-
thy” (PART) has recently emerged to characterize the many patients with mainly neurofibril-
lary pathology and only few or none Aβ deposits [35, 36]. Whether this condition represents
an independent disease remains the subject of debate; several authors have suggested that
PART belongs to the AD spectrum, with some patients beginning their disease by an initial
spreading of tau lesions that precedes Aβ accumulation [4, 37]. CSF biomarkers represents an
Table 3. Change over time in profiles defined by CSF biomarkers profiles in 70 patients with 2 assessments of bio-
markers. Profiles are based on CSF Aβ42, CSF Tau, and CSF p-Tau (NIA-AA classification).
Profile at time 2
Profile at time 1 A-N- A+N- A+N+ A-N+ Total
A-N- 4 (30) 7 (54) 1 (8) 1 (8) 13
A+N- 5 (22) 14 (61) 3 (13) 1 (4) 23
A+N+ 0 (0) 2 (10) 16 (80) 2 (10) 20
A-N+ 1 (7) 1 (7) 5 (36) 7 (50) 14
https://doi.org/10.1371/journal.pone.0217026.t003
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opportunity to test in-vivo these hypothesis and the fact that one third of our patients initially
classified as A-N+ evolved to an A+N+ profile supports this hypothesis. Furthermore, many
neuropathological studies have reported that neurofibrillary tangles accumulation is a com-
mon feature of ageing [38–40]. Current methods lack sensitivity to detect minimal tangle pres-
ence in the entorhinal area and hippocampus, more sensitive methods for tau detection may
in the future increase the proportion of A-N+ patients.
This study has several strengths, including its large size which allowed us to cover a wide
spectrum of AD pathology, the inclusion of data from 18 memory clinics, and the fact that the
analyses of CSF were performed in a single biochemistry department which prevents intersite
variability [29]. One of the main limitations is that most of the patients had only one CSF bio-
markers assessment, which allows only cross-sectional analysis. We however checked the evo-
lution of biomarkers profiles in 70 patients who had 2 lumbar punctures. Future large scale
studies with repeated CSF biomarkers assessments and large duration of follow-up will be
helpful to better understand the kinetics of these biomarkers, especially at the early stage of the
disease. Another limitation is that the four profiles were defined using CSF biomarkers rather
than independent criteria (PET-imaging, neuropathology).
In conclusion, this report describes the relationship between CSF Aβ42 and CSF Tau in a
large and multicentric population of patients who were referred to memory clinics for further
assessment of cognitive disorders. We found that the nature of the association between these
biomarkers was dependent of the biomarker based profile of the patients: positive association
Fig 3. Two distinct patterns: Theoretical framework of the association between CSF Aβ42 and CSF Tau. In green,
patients with normal profiles have an increase of CSF Aβ42 followed by a decrease after the progression of tau pathology.
In red, patients with isolated low CSF Aβ42 had a stable level before declining.
https://doi.org/10.1371/journal.pone.0217026.g003
CSF biomarkers associations in Alzheimer’s disease
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in normal profile, negative association in SNAP and AD profiles, lack of association in amy-
loidosis only subjects. These results plead for an increase of CSF Aβ42 early in the disease,
before its decline, especially among non-APOE4 subjects. This pattern may explain why some
patients with neurodegeneration only markers convert to AD profiles only over time.
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S1 Table. Comparison of linear and quadratic models for the association between CSF Tau
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